Not so fast for AbbVie in SEZ6
A phase 3 trial is downgraded, and the second line now looks like the main focus for turmetabart adizutecan.
AbbVie makes a bigger bet on SEZ6
But first it will need to identify the optimal dose in first-line small-cell lung cancer.
ASCO 2024 preview – jury still out on AbbVie's cancer push
SEZ6 looks promising but early, while questions remain around toxicity with AbbVie's cMet ADCs.
A cancer pipeline cull from AbbVie
Early-stage assets missing from the group’s pipeline include several ADCs, as the acquisition of ImmunoGen looms.
